Translocator Protein (18 kDa) as a Target for Novel Anxiolytics with a Favourable Side‐Effect Profile
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Anxiety disorders are frequent and highly disabling diseases with considerable socio‐economic impact. In the treatment of anxiety disorders, benzodiazepines (BZDs) as direct modulators of the GABA A receptor are used as emergency medication because of their rapid onset of action. However, BZDs act also as sedatives and rather quickly induce tolerance and abuse liability associated with withdrawal symptoms. Antidepressants with anxiolytic properties are also applied as first line long‐term treatment of anxiety disorders. However, the onset of action of antidepressants takes several weeks. Obviously, novel pharmacological approaches are needed that combine a rapid anxiolytic efficacy with the lack of tolerance induction, abuse liability and withdrawal symptoms. Neurosteroids are potent allosteric modulators of GABA A receptor function. The translocator protein (18 kDa) (TSPO) plays an important role for the synthesis of neurosteroids by promoting the transport of cholesterol from the outer to the inner mitochondrial membrane, which is the rate‐limiting step in neurosteroidogenesis. Etifoxine not only exerts anxiolytic effects as a TSPO ligand by enhancing neurosteroidogenesis, but also acts as a weak direct GABA A receptor enhancer. The TSPO ligand XBD173 enhances GABAergic neurotransmission via the promotion of neurosteroidogenesis without direct effects at the GABA A receptor. XBD173 counteracts pharmacologically‐induced panic in rodents in the absence of sedation and tolerance development. Also in humans, XBD173 displays antipanic activity and does not cause sedation and withdrawal symptoms after 7 days of treatment. XBD173 therefore appears to be a promising candidate for fast‐acting anxiolytic drugs with less severe side‐effects than BZDs. In this review, we focus on the pathophysiology of anxiety disorders and TSPO ligands as a novel pharmacological approach in the treatment of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors
Farrant, M., & Nusser, Z. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1625 · Cited by 2,081
Neurosteroids: endogenous regulators of the GABAA receptor
Belelli, D., & Lambert, J. J. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1703 · Cited by 1,159
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., Groyer, G., Adams, D., & Schumacher, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3295 · Cited by 930
Self-citationRussell, D. W., & Setchell, K. D. R. (1992) · Biochemistry · doi:10.1021/bi00135a001 · Cited by 819
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752
McEnery, M. W., Snowman, A. M., Trifiletti, R. R., & Snyder, S. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3170 · Cited by 708
Enigma of the peripheral benzodiazepine receptor
Gavish, M., Bachman, I., Shoukrun, R., Katz, Y., Veenman, L., Weisinger, G., & Weizman, A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01424-8 · Cited by 512
Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Chen, M.-K., & Guilarte, T. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.004 · Cited by 506
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499
Cited by
Anxiety disorders and GABA neurotransmission: a disturbance of modulation
Gauthier, I., & Nuss, P. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s58841 · Cited by 466
The role of allopregnanolone in depression and anxiety
Schüle, C., Nothdurfter, C., & Rupprecht, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.09.003 · Cited by 312
Self-citationGABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response
Gunn, B. G., Cunningham, L., Mitchell, S. G., Swinny, J. D., Lambert, J. J., & Belelli, D. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.06.001 · Cited by 149
Leydig cell aging and hypogonadism
Beattie, M. C., Adekola, L., Papadopoulos, V., Chen, H., & Zirkin, B. R. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.02.014 · Cited by 139
Self-citationScholz, R., Caramoy, A., Bhuckory, M. B., Rashid, K., Chen, M., Xu, H., Grimm, C., & Langmann, T. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0422-5 · Cited by 111
“Classical synthetic TSPO ligands such as the benzodiazepine derivative 4′-chlorodiazepam (Ro5-4864) and the isoquinoline carboxamide PK11195 directly enhance GABAergic neurotransmission [28].”
Background
Metadata
- Authors
- Nothdurfter, C., Rammes, G., Baghai, T. C., Schüle, C., Schumacher, M., Papadopoulos, V., & Rupprecht, R.
- Venue
- Journal of Neuroendocrinology
- Publisher
- Wiley
- Published
- 2011-12-20
- Volume
- 24
- Issue
- 1
- Pages
- 82-92
- ISSN
- 0953-8194 (ISSN-L)
- 1365-2826
- OpenAlex
- W1511789551
- Cited by
- 71
- References
- 29
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translocator Protein (18 kDa) as a Target for Novel Anxiolytics with a Favourable Side‐Effect Profile. https://app.cochat.ai/papers/10.1111/j.1365-2826.2011.02166.x
- The paper
- Nothdurfter, C., Rammes, G., Baghai, T. C., Schüle, C., Schumacher, M., Papadopoulos, V., & Rupprecht, R. (2012). Translocator Protein (18 kDa) as a Target for Novel Anxiolytics with a Favourable Side‐Effect Profile. Journal of Neuroendocrinology. https://doi.org/10.1111/j.1365-2826.2011.02166.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.